Iodine status during pregnancy in a region of mild-to-moderate iodine deficiency is not associated with adverse obstetric outcomes ; results from the Avon Longitudinal Study of Parents and Children (ALSPAC) by Torlinska, Barbara et al.
nutrients
Article
Iodine Status during Pregnancy in a Region of
Mild-to-Moderate Iodine Deficiency is not Associated
with Adverse Obstetric Outcomes; Results from the
Avon Longitudinal Study of Parents and Children
(ALSPAC)
Barbara Torlinska 1 ID , Sarah C. Bath 2,*, Aisha Janjua 3,4, Kristien Boelaert 5,6 and Shiao-Yng Chan 7
1 Institute of Applied Health Research, University of Birmingham, Birmingham B15 2TT, UK;
b.torlinska@bham.ac.uk
2 Department of Nutritional Sciences, Faculty of Health and Medical Sciences, University of Surrey, Guildford,
Surrey GU2 7XH, UK
3 Birmingham Heartlands Hospital, Birmingham B9 5SS, UK; aishajanjua@doctors.org.uk
4 Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK
5 Institute of Metabolism and Systems Research, University of Birmingham, Birmingham B15 2TT, UK;
k.boelaert@bham.ac.uk
6 Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Edgbaston,
Birmingham B15 2TH, UK
7 Department of Obstetrics and Gynaecology, Yong Loo Lin School of Medicine,
National University of Singapore, 1E Kent Ridge Road, Singapore 119228, Singapore; obgchan@nus.edu.sg
* Correspondence: s.bath@surrey.ac.uk; Tel.: +44-148-368-3631
Received: 31 January 2018; Accepted: 22 February 2018; Published: 1 March 2018
Abstract: Severe iodine deficiency during pregnancy has been associated with pregnancy/neonatal
loss, and adverse pregnancy outcomes; however, the impact of mild–to–moderate iodine insufficiency,
though prevalent in pregnancy, is not well-documented. We assessed whether mild iodine deficiency
during pregnancy was associated with pregnancy/infant loss, or with other adverse pregnancy
outcomes. We used samples and data from the Avon Longitudinal Study of Parents and Children
(ALSPAC), from 3140 singleton pregnancies and from a further 42 women with pregnancy/infant
loss. The group was classified as mildly-to-moderately iodine deficient with a median urinary iodine
concentration of 95.3 µg/L (IQR 57.0–153.0; median urinary iodine-to-creatinine ratio (UI/Creat)
124 µg/g, IQR 82–198). The likelihood of pregnancy/infant loss was not different across four UI/Creat
groups (<50, 50–149, 150–250, >250 µg/g). The incidence of pre-eclampsia, non-proteinuric gestational
hypertension, gestational diabetes, glycosuria, anaemia, post-partum haemorrhage, preterm delivery,
mode of delivery, being small for gestational age, and large for gestational age did not differ
significantly among UI/Creat groups, nor were there any significant differences in the median
UI/Creat. We conclude that maternal iodine status was not associated with adverse pregnancy
outcomes in a mildly-to-moderately iodine-deficient pregnant population. However, in view of the
low number of women with pregnancy/infant loss in our study, further research is required.
Keywords: iodine; pregnancy; obstetric; UK; Avon Longitudinal Study of Parents and Children
(ALSPAC)
1. Introduction
Iodine is essential for the production of thyroid hormones and is particularly important during
pregnancy and early life owing to its role in brain development. While there has been enormous
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progress in the eradication of iodine deficiency in many countries worldwide (through the use of
iodised salt), iodine deficiency remains a problem in pregnant women in many countries, including
the UK [1]. The World Health Organization (WHO) categorises iodine adequacy in a pregnant
population if the median urinary iodine concentration (UIC) is 150–249 µg/L; a median UIC in
pregnancy of <150 µg/L is considered insufficient, 250–499 µg/L as above requirements and >500 µg/L
as excessive [2].
Significant neurodevelopmental impairment occurs with severe maternal iodine deficiency during
pregnancy, including the development of cretinism [3]. Correction of severe iodine deficiency in
the population decreases the rates of cretinism [4] and increases offspring IQ [5]. More recently,
observational studies have found associations between mild-to-moderate iodine deficiency during
pregnancy and poorer offspring cognition, IQ, and school performance [6–10].
Beyond the effects on brain development, severe maternal iodine deficiency has also been
associated with increased perinatal and infant mortality, recurrent miscarriage and preterm delivery,
and significant improvements were observed with iodine supplementation [11,12]. Whether mild
iodine deficiency or excess iodine intake can adversely affect pregnancy outcomes is less clear.
One retrospective study in Senegal suggested a dose-dependent relationship between the degree
of iodine deficiency and the risk of pregnancy loss but this study was subject to recall bias [13].
A prospective observational study reporting outcomes of 390 pregnancies in a mildly iodine-deficient
population in Thailand reported increased risks of preterm birth and low birthweight in those with
iodine insufficiency compared with those who were iodine sufficient, but there was no significant
difference in stillbirth rates [14]. A randomised controlled trial was conducted in India and Thailand
evaluating iodine supplementation starting from the end of the first trimester of pregnancy with the
primary outcomes of change in maternal thyroid function and child neurodevelopment. It reported
no significant change in rates of preterm birth or low birth weight; however, it was underpowered
to detect differences in obstetric outcomes, and perinatal losses were not specifically reported [15].
Furthermore, the women in the trial were quite likely to be iodine sufficient, especially in India where
the baseline iodine status was in the adequate range [16].
Even women living in countries classed as iodine replete are commonly iodine deficient in
pregnancy [1] because of physiologically increased iodine requirements in pregnancy due to increased
renal clearance, increased thyroid hormone synthesis and fetal-placental requirements [17–19]. With the
success of population-based iodine supplementation programmes and with additional routine oral
iodine supplementation in pregnancy advocated in parts of the world [20,21], regardless of the iodine
status of the population the potential issues associated with iodine excess in pregnancy have also
recently surfaced in some countries, including adverse effects on maternal thyroid function [22]. Thus,
it is important to establish if mild derangements in iodine status during pregnancy, both insufficiency
and iodine excess, is associated with adverse obstetric outcomes. The implications of mild iodine
deficiency are of relevance to the UK as studies have reported mild-to-moderate iodine deficiency in
teenage schoolgirls [23] and in pregnant women [24–27].
This study used samples and data from pregnancies in the UK Avon Longitudinal Study of Parents
and Children (ALSPAC) birth cohort, where we have previously documented an adverse impact of
maternal iodine insufficiency on child neurocognitive development [6]. In this study, we investigated
whether insufficient and excess iodine status during pregnancy was associated with adverse obstetric
outcomes defined as: (i) pregnancy loss or infant loss by the age of 1 year; (ii) common obstetric
complications including hypertensive disorders of pregnancy, glucose derangements, anaemia,
preterm delivery, caesarean delivery, post-partum haemorrhage and babies born small or large for
gestational age.
2. Materials and Methods
ALSPAC recruited pregnant women from the county of Avon in the south-west of the UK,
with expected dates of delivery 1 April 1991 to 31 December 1992 [28,29]. Among the 14,541 pregnant
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women enrolled; there were 553 miscarriages, perinatal losses and infant deaths, and 13,988 children
survived for at least 12 months. Ethical approval for the study was obtained from the ALSPAC Ethics
and Law Committee and the local research ethics committees [30]. Please note that the study website
contains details of all the data that is available through a fully searchable data dictionary [31].
For the current study, women were selected on the basis of a singleton pregnancy and if they had at
least one existing measure of urinary iodine-to-creatinine (UI/Creat) during pregnancy; these existing
measures were from previous and ongoing studies examining the relationship between maternal iodine
status and child IQ at age 8 years and the measures were already available in the ALSPAC resource
(n = 3524). Furthermore, we selected women who experienced pregnancy/infant loss up to the age
of 1 year and who had an available antenatal urine sample for iodine analysis (n = 46). In all cases
where there was a repeat urine sample, the earliest available sample was used; this was done as we
postulated that the impact of iodine status on pregnancy outcome is greatest during early pregnancy.
2.1. Laboratory Analysis
Iodine concentration was measured in the urine samples from women with fetal/infant loss up
to 1 year in the same laboratory (Trace Element Unit, Southampton General Hospital, Southampton,
UK) and using the same methodology (i.e., using inductively coupled plasma mass spectrometer
(ICP-MS)) as was used for all previous measures of iodine concentration in ALSPAC urine samples
(n = 3524); the details of this method have been described in full previously [6]. The results were verified
for accuracy using certified reference material, Seronorm Trace Elements Urine (Nycomed Pharma,
Norway; with a certified iodine content of 84 µg/L and 305 µg/L for Seronorm Urine Level 1 and
2 respectively). The within run precision was 7.0% at 84 µg/L and 5.8% at 294 µg/L. The between
run precision was 4.4% at 43 µg/L, 4.9% at 83 µg/L, 3.6% at 149 µg/L, and 2.3% at 294 µg/L.
As previously, urinary creatinine was determined by the UniCel DxC Synchron Clinical System
Analyzer (Beckman Coulter, High Wycombe, UK) using the Jaffe rate method.
2.2. Classification of Iodine Status
The median urinary iodine concentration (UIC) value of the group was compared with the WHO
UIC cut-offs for iodine adequacy in pregnancy [2]. As UIC cannot be used to estimate iodine status in an
individual (as a result of day-to-day variation and urine dilution), we used the iodine-to-creatinine ratio
(UI/Creat) for analyses that related iodine status to pregnancy outcomes. This is because the UI/Creat
corrects for some of the variation in dilution among spot-urine samples; the iodine-to-creatinine ratio
produces a better measure of individual iodine status, especially when the age and sex of the individual
is taken into account [32], as is the case in a cohort of pregnant women.
We report iodine status in two ways, as the iodine concentration (UIC) in µg/L and as the
iodine-to-creatinine ratio (UI/Creat) in µg/g. As in our previous research on iodine status in the
ALSPAC cohort, we grouped women according to their UI/Creat result. The groups were defined
as <50 µg/g, 50–149.9 µg/g, 150–249.9 µg/g, and ≥250 µg/g; these groups, broadly speaking relate
to severely deficient, mildly-to-moderately deficient, sufficient, and more-than adequate iodine,
respectively, based on WHO [2] and other published criteria [3]. We investigated the relationship
between UI/Creat during pregnancy with obstetric outcomes in women who had infants alive at 1 year
by comparing the incidence of common pregnancy complications in the four iodine status categories.
2.3. Obstetric Outcomes
We examined the following obstetric outcomes: (i) hypertensive disorders in pregnancy;
(ii) glucose derangement; (iii) anaemia; (iv) post-partum haemorrhage; (v) preterm birth; (vi) mode
of delivery; and (vii) birthweight. Details of obstetric outcomes were extracted from hospital records
following delivery. Hypertensive disorders in pregnancy was defined by a systolic BP > 139 mmHg or
a diastolic BP > 89 mmHg on 2 or more occasions beyond 20 weeks gestation, as previously defined
in this cohort [33], and included two subgroups: pre-eclampsia (at least 1+ proteinuria with episode
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of hypertension) and non-proteinuric gestational hypertension. We examined any form of glucose
derangement in pregnancy, including: (i) gestational diabetes (diagnosis obtained from medical
records in women with no history of pre-existing diabetes); (ii) glycosuria (dipstick glycosuria of ++ or
more on at least two occasions in women with no evidence of pre-existing or gestational diabetes);
and (iii) hyperglycaemia (including cases of any abnormality in fasting bloods, serial blood sugars,
glucose-tolerance tests or fructosamine evaluations). Anaemia was defined by a haemoglobin of
between 4.0 g/dL and 9.9 g/dL. Post-partum haemorrhage was defined by an estimated blood loss of
over 500 mL around the time of delivery. Gestational age was determined by the last menstrual period
but adjusted if early pregnancy ultrasound measurements differed by 2 weeks or more, according to the
clinical protocol in use at the time. Preterm delivery was defined as birth before 37 completed weeks
of pregnancy, including both spontaneous onset of labour and iatrogenic deliveries. All caesarean
section deliveries were considered as a single group whilst vaginal deliveries were subdivided into
spontaneous or instrumental/assisted/breech deliveries. Birthweights were customised for sex,
gestational age, maternal body mass index (BMI), parity and ethnicity as previously described [34]
to identify babies who were small for gestational age (<10th percentile) and large for gestational age
(>90th percentile). The outcomes were analysed within the subsets of available data for each individual
outcome. No data imputation was conducted.
2.4. Statistical Analysis
As a result of concern that the urine samples had been contaminated with iodine from urine
test strips [6], women with excessively high urinary iodine concentration (>500 mg/L) and/or high
iodine-to-creatinine ratio (>700 mg/g) were excluded from statistical analysis (those with a child alive
at 1 year: n = 414, 11.7%; those with pregnancy/infant loss n = 5, 10.9%). If a woman had a later
urine sample (with a result that was considered to be uncontaminated) that was used to replace the
contaminated result (those with a child alive at 1 year n = 50; those with pregnancy/infant loss n = 1).
We also excluded women who were taking thyroid hormone medication during pregnancy (those with
a child alive at 1 year n = 20, 0.5%; those with pregnancy/infant loss, n = 0, 0%). This resulted in a total
of 3140 women with a child alive at 1 year, and 42 women with a pregnancy/infant loss.
UI/Creat was not normally distributed and, therefore, differences between groups were compared
using a non-parametric test (Mann–Whitney U test). Additionally, UI/Creat were stratified into four
iodine status groups as described above. Chi-square tests were used when comparing groups of iodine
status with the presence/absence of pregnancy outcomes, and one-way analysis of variance (ANOVA)
was used to compare continuous data between grouped UI/Creat.
Likelihood of fetal and neonatal death events was compared to live controls. Adverse pregnancy
outcomes were studied within those with live babies. Logistic regression was used to examine
the association between maternal iodine status (as the four groups of UI/Creat) and likelihood of
adverse pregnancy outcomes, with women in the 150–249 µg/g group as the reference category.
For each pregnancy outcome, crude and adjusted odds ratios of the pregnancy outcomes (OR and
AOR) were calculated. The likelihood of being small or large for gestational age were calculated
against odds of being appropriately grown for gestational age. The models were adjusted for mother’s
BMI (pre-pregnancy) and age, parity (zero, one, two, three or more), cigarette smoking during early
pregnancy (yes/no) and trimester of UI/Creat collection.
The statistical significance was assumed a priori at 0.05 level; the 95% confidence intervals
(CI) were calculated accordingly. All analyses were conducted using IBM SPSS Statistics version 23
(IBM Corp., Armonk, NY, USA).
3. Results
In total we included 42 cases of pregnancy/infant loss up to age 1 year. This included fetal deaths
and stillbirths between 20–42 weeks’ gestation (n = 11), neonatal deaths within the first month of life
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(n = 24), and child deaths between 1–12 months (n = 7). We also had uncontaminated UI/Creat results
from a total of 3140 women with babies who survived beyond the first year.
The median UIC in the entire cohort of women included in this study (n = 3182) was 95.3 µg/L
(IQR 57.0–153.0), indicating mild-to-moderate iodine deficiency in this group of pregnant women [35].
The median (IQR) urinary iodine-to-creatinine (UI/Creat) was 124 (82–198) µg/g. The UI/Creat was
<50 µg/g in 5.1% (n = 161) of the cohort, 50–149.9 µg/g in 56.4% (n = 1794), 150–249.9 µg/g in 21.8%
(n = 693) and greater than 250 µg/g in 16.8% (n = 534).
3.1. Iodine Status and Pregnancy Loss
We compared women with infants alive at 1 year (n = 3140) to those with pregnancy/infant loss
(n = 42) (Table 1). There were no significant differences in maternal BMI, age, parity and sex of the baby.
Furthermore, there were no differences in other potential confounders, such as history of miscarriage
and cigarette smoking. However, the urine samples used for UI/Creat measurements were collected
significantly earlier in gestation in the group with a live infant compared with the pregnancy/infant
loss group (p < 0.001). The median UI/Creat of those with pregnancy/infant loss and those with babies
alive at 1 year was not significantly different (144 vs. 123 µg/g; p = 0.07).
Amongst those who experienced a pregnancy/child loss, the likelihood of being iodine insufficient
or more-than adequate during the pregnancy were no different to those whose child was alive at one
year. Adjustment for confounders (trimester of urine collection, BMI, age, parity, history of miscarriage
and smoking) did not alter the conclusions.
Table 1. Demographic characteristics and urinary iodine-to-creatinine (UI/Creat) measurements in
women with a child alive at 1 year and those who experienced pregnancy/infant loss up to 1 year.
Child Alive at 1 Year
n = 3140 (98.7%)
Pregnancy/Infant Loss
n = 42 (1.3%) p Value
2
Body mass index (BMI) (kg/m2) 1 22.25 (20.3–24.5) 21.7 (20.1–24.5) 0.36
Underweight (<18.5) 114 (4.0) 2 (7.7)
0.53
Healthy weight (18.5–24.9) 2129 (74.8) 20 (76.9)
Overweight (25–29.9) 460 (16.2) 4 (15.4)
Obese (≥;30) 142 (5.0) 0 (0)
Age (years), median [IQR] 29 (26–32) 28 (26–31) 0.20
Parity
0 1428 (47.3) 17 (43.6)
0.27
1 1031 (34.2) 11 (28.2)
2 426 (14.1) 7 (17.9)
3+ 132 (4.4) 4 (10.3)
History of miscarriage 598 (19.8) 8 (20.5) 0.91
Cigarette-smoking 1294 (42.2) 16 (41.0) 0.88
Child sex
Male 1550 (49.4) 26 (61.9) 0.11
Trimester of urine sample
1st (≤12 weeks) 1735 (55.3) 16 (39.0)
<0.0012nd (13–27 weeks) 1327 (42.3) 19 (46.3)
3rd (≥28 weeks) 78 (2.5) 6 (14.6)
UI/Creat median [IQR] (µg/g) 123 (82–197) 144 (103–209) 0.07
UI/Creat groups
<50 µg/g 161 (5.1) 0 (0)
0.24
50–149.9 µg/g 1773 (56.5) 21 (50.0)
150–249.9 µg/g 680 (21.7) 13 (31.0)
≥250 µg/g 526 (16.8) 8 (19.0)
1 Data are median (25th, 75th percentile) for continuous data and n (%) for categorical data. 2 p value from chi-square
test for categorical data and from Mann–Whitney U for continuous data.
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3.2. Iodine Status and Pregnancy Outcomes among Women with Infants Alive at One Year
There were significant differences between the four UI/Creat status groups in terms of BMI, age,
parity and trimester of UI/Creat collection (Table 2). The <50 µg/g group was associated with a higher
BMI, younger age, lower parity and urinary collection earlier in pregnancy.
Table 2. Demographic characteristics across groups categorised by urinary iodine-to-creatinine ratio
(UI/Creat) of 3140 pregnant women with babies alive at one year.
No. Available
UI/Creat Groups (µg/g)
p Value 2
<50 50–149.9 150–249.9 ≥250
Age (years) 3122
n 158 1764 675 525
Mean (SD) 27.2 (4.3) 29.3 (4.5) 29.9 (4.3) 29.9 (4.4) <0.001
BMI (kg/m2) 1 2845
Underweight (<18.5) 6 (4.2) 60 (3.7) 26 (4.2) 22 (4.6)
<0.001Healthy weight (18.5–24.9) 96 (67.6)
1180
(73.5) 482 (77.6) 371 (77.9)
Overweight (25–29.9) 25 (17.6) 278 (17.3) 89 (14.3) 68 (14.3)
Obese (≥30) 15 (10.6) 88 (5.5) 24 (3.9) 15 (3.2)
Parity 1 3017
0 96 (62.7) 813 (47.7) 285 (43.6) 234 (46.2)
0.007
1 38 (24.8) 591 (34.7) 230 (35.2) 172 (33.9)
2 17 (11.1) 227 (13.3) 105 (16.1) 77 (15.2)
3+ 2 (1.3) 72 (4.2) 34 (5.2) 24 (4.7)
Cigarette-smoking 1 3067 75 (49.0) 720 (41.7) 287 (43.0) 212 (40.8) 0.30
History of miscarriage 1 3022 21 (13.8) 332 (19.4) 140 (21.5) 105 (20.6) 0.18
Child sex 1 3140
Male 67 (41.6) 880 (49.6) 354 (52.1) 249 (47.3) 0.08
Trimester of urine collection 1 3140
1st (≤12 weeks) 122 (75.8) 1114(62.8) 331 (48.7) 168 (31.9)
2nd (13–27 weeks) 37 (23.0) 628 (35.4) 325 (47.8) 337 (64.1) <0.001
3rd (≥28 weeks) 2 (1.2) 31 (1.7) 24 (3.5) 21 (4.0)
1 Values are n (%). 2 p value from chi-squared test for categorical data and analysis of variance (ANOVA) for
continuous data.
The overall incidence and the odds of hypertensive disorders in pregnancy and the subgroups of
pre-eclampsia and non-proteinuric gestational hypertension were not significantly different between
the four groups of iodine status (Table 3). Similarly, the overall incidence and odds of any form of
glucose derangement in pregnancy, as well as the subgroups of gestational diabetes, glycosuria and
hyperglycaemia in pregnancy were no different between the iodine status groups. The incidence
and odds of anaemia both antenatally and during the first 14 days post-partum as well as the
incidence of post-partum haemorrhage were not different either. There were no differences in preterm
delivery rates or in the mode of delivery between groups. Of the 1954 cases where customised
birthweight percentiles [34] could be calculated, the mean (SD) percentiles were similar across the
groups (46.3% (29.5) with UI/Creat less than 50 µg/g (n = 95), 50.7% (28.9) with UI/Creat 50–149.9 µg/g
(n = 1132), 48.7% (28.4) with UI/Creat 150–249.9 µg/g (n = 392) and 46.9% (29.1) with UI/Creat greater
than 250 µg/g (n = 335)) and the incidence and odds of being both small for gestational age and large
for gestational age were not significantly different between iodine groups. We also modelled the
likelihood (odds ratio) of adverse pregnancy outcomes in various UI/Creat status groups compared
with sufficient UI/Creat, adjusting for the confounders of mothers’ BMI, age, parity, smoking and
trimester of UI/Creat collection (Table 3). There were no significant differences in the adjusted odds
ratios for any of the outcomes.
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Table 3. Likelihood of each adverse pregnancy outcome in urinary iodine-to-creatinine ratio (UI/Creat)
groups; reference group 150–249 µg/g. Data based on 3140 pregnant women with infants alive at
one year.
UI/Creat
(µg/g)
Group
n/N 1
Incidence Unadjusted OR Adjusted OR 3
(%) p Value 2 OR (CI) pValue AOR (CI) pValue
Hypertensive disorders of pregnancy
<50
50–149
5150–249
5≥250
29/158
277/1757
93/671
87/522
18.4
15.8
13.9
16.7
0.43
1.4 (0.9–2.2)
1.2 (0.9–1.5)
1.0
1.2 (0.9–1.7)
0.15
0.24
0.18
1.2 (0.7–1.9)
1.1 (0.8–1.4)
1.0
1.3 (0.9–1.8)
0.57
0.66
0.17
Pre-eclampsia
<50
50–149
150–249
≥250
2/158
40/1757
10/671
10/522
1.3
2.3
1.5
1.9
0.60
0.8 (0.2–3.9)
1.5 (0.8–3.1)
1.0
1.3 (0.5–3.1)
0.83
0.23
0.57
0.6 (0.1–3.1)
1.2 (0.6–2.6)
1.0
1.5 (0.6–3.7)
0.57
0.61
0.41
Non-proteinuric gestational
hypertension
<50
50–149
150–249
≥250
27/158
237/1757
83/671
77/522
17.1
13.5
12.4
14.8
0.38
1.5 (0.9–2.3)
1.1 (0.8–1.4)
1.0
1.2 (0.9–1.7)
0.12
0.47
0.23
1.2 (0.7–2.1)
1.0 (0.8–1.4)
1.0
1.2 (0.9–1.8)
0.39
0.82
0.26
Any glucose derangement 4
<50
50–149
150–249
≥250
12/94
124/1116
41/395
43/333
12.8
11.1
10.4
12.9
0.70
1.3 (0.6–2.5)
1.1 (0.7–1.6)
1.0
1.3 (0.8–2.0)
0.50
0.69
0.29
1.1 (0.5–2.3)
1.0 (0.7–1.5)
1.0
1.4 (0.9–2.3)
0.79
0.97
0.17
Gestational diabetes
<50
50–149
150–249
≥250
1/154
7/1699
3/654
7/514
0.6
0.4
0.5
1.4
0.10
1.4 (0.1–13.7)
0.9 (0.2–3.5)
1.0
3.0 (0.8–11.6)
0.76
0.88
0.11
1.6 (0.2–17.1)
0.5 (0.1–2.3)
1.0
3.3 (0.8–13.1)
0.69
0.36
0.15
Glycosuria
(2+ or more)
<50
50–149
150–249
≥250
5/158
53/1757
28/671
22/522
3.2
3.0
4.2
4.2
0.40
0.8 (0.3–2.0)
0.7 (0.4–1.1)
1.0
1.0 (0.6–1.8)
0.56
0.16
0.97
0.7 (0.2–2.0)
0.7 (0.4–1.2)
1.0
0.9 (0.5–1.8)
0.46
0.18
0.84
Hyperglycaemia during pregnancy
<50
50–149
150–249
≥250
9/96
115/1149
34/402
42/339
9.4
10.0
8.5
12.4
0.36
1.1 (0.5–2.4)
1.2 (0.8–2.5)
1.0
1.5 (0.9–2.5)
0.77
0.36
0.08
1.0 (0.5–2.4)
1.1 (0.7–1.7)
1.0
1.6 (1.0–2.7)
0.91
0.69
0.07
Anaemia during pregnancy
<50
50–149
150–249
≥250
10/96
123/1149
47/402
34/339
10.4
10.7
11.7
10.0
0.90
0.9 (0.4–1.8)
0.9 (0.6–1.3)
1.0
0.8 (0.5–1.3)
0.73
0.59
0.47
1.2 (0.5–2.5)
1.0 (0.6–1.4)
1.0
0.9 (0.6–1.5)
0.69
0.81
0.75
Anaemia < 14 days postpartum
<50
50–149
150–249
≥250
17/158
224/1755
78/671
53/522
10.8
12.8
11.6
10.2
0.40
0.9 (0.5–1.6)
1.1 (0.8–1.5)
1.0
0.9 (0.6–1.2)
0.76
0.45
0.42
0.6 (0.3–1.1)
1.0 (0.7–1.4)
1.0
0.8 (0.6–1.2)
0.11
0.91
0.33
Postpartum haemorrhage
<50
50–149
150–249
250+
15/95
164/1133
46/387
49/336
15.8
14.5
11.9
14.6
0.58
1.4 (0.7–2.6)
1.3 (0.9–1.8)
1.0
1.3 (0.8–1.9)
0.31
0.20
0.29
1.2 (0.6–2.3)
1.2 (0.8–1.7)
1.0
1.3 (0.8–2.0)
0.61
0.46
0.34
Preterm delivery
<50
50–149
150–249
≥250
9/158
80/1764
29/675
28/525
5.7
4.5
4.3
5.3
0.76
1.3 (0.6–2.9)
1.1 (0.7–1.6)
1.0
1.3 (0.7–2.1)
0.45
0.80
0.40
1.3 (0.6–3.0)
1.0 (0.6–1.6)
1.0
1.4 (0.8–2.4)
0.48
0.98
0.29
Caesarean section
<50
50–149
150–249
≥250
14/95
192/1113
63/386
61/335
14.7
17.3
16.3
18.2
0.84
0.9 (0.5–1.7)
1.1 (0.8–1.5)
1.0
1.1 (0.8–1.7)
0.71
0.68
0.50
0.6 (0.3–1.3)
0.9 (0.7–1.3)
1.0
1.0 (0.7–1.6)
0.22
0.66
0.88
Assisted/breech delivery among all
vaginal births
<50
50–149
150–249
≥250
23/81
231/921
67/323
72/274
28.4
25.1
20.1
26.3
0.70
1.2 (0.7–2.2)
1.3 (0.9–1.8)
1.0
1.3 (0.9–1.9)
0.50
0.12
0.18
1.2 (0.7–2.3)
1.1 (0.8–1.6)
1.0
1.0 (0.7–1.6)
0.50
0.45
0.93
Small for gestational age 4
<50
50–149
150–249
≥250
13/95
111/1132
36/392
43/335
13.7
9.8
9.2
12.8
0.23
1.6 (0.8–3.0)
1.1 (0.7–1.6)
1.0
1.5 (0.9–2.3)
0.19
0.72
0.12
1.5 (0.7–3.1)
1.0 (0.7–1.6)
1.0
1.5 (0.9–2.5)
0.29
0.87
0.13
Large for gestational age 4
<50
50–149
150–249
≥250
5/95
124/1132
30/392
26/335
5.3
11.0
7.7
7.8
0.06
0.7 (0.3–1.8)
1.5 (1.0–2.3)
1.0
1.0 (0.6–1.8)
0.42
0.06
0.96
0.7 (0.2–1.8)
1.4 (0.9–2.2)
1.0
1.3 (0.6–1.9)
0.66
0.12
0.80
1 Values are number affected/total in the category (n/N). 2 p value from Chi square. 3 Logistic regression model
adjusted for mother’s BMI and age, parity, cigarette smoking, and trimester of UI/Creat collection. 4 Customized
for maternal BMI, parity, sex and gestational age [34]; likelihood of being small or large for gestational age were
calculated against odds of being appropriately grown for gestational age.
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Additionally, we compared the UI/Creat as a continuous variable in those with and without a
pregnancy complication of interest. There were no significant differences in the median UI/Creat
when women were dichotomised based on the presence or absence of the studied outcome (Table 4).
We performed a sensitivity analysis limited to cases where the UI/Creat ratio was obtained from a
first trimester sample. Similar to the entire cohort, there were significant differences in BMI, parity and
age of women across four UI/Creat categories (Supplementary Table S1). No differences were observed
in the incidence of adverse pregnancy outcomes (Supplementary Table S2) except for hyperglycaemia
during pregnancy being more likely in mothers with UIC/Creat ≥ 250 µg/g compared with those
in 150–249 µg/g group (AOR = 2.5 (1.1–5.5), p = 0.03), which is most likely a chance finding (Type 1
error). There were no significant differences in the median UIC/Creat between the groups with and
without a pregnancy complication of interest (Supplementary Table S3).
Table 4. Comparison of urinary iodine-to-creatinine ratio (UI/Creat; µg/g) in those where pregnancy
complications were either present or absent. Data based on 3140 pregnant women with infants alive at
one year.
Median Urinary Iodine-to-Creatinine Ratio (µg/g) 1
p Value 2
n Complication Present n Complication Absent
Hypertensive disorders of pregnancy 486 119 (80–199) 2622 124 (82–197) 0.63
Pre-eclampsia 62 117 (89–192) 3046 124 (82–198) 0.86
Non-proteinuric gestational hypertension 424 121 (79–202) 2684 124 (83–197) 0.55
Any glucose derangement 220 124 (78–210) 1718 123 (83–192) 0.89
Gestational diabetes 18 170 (95–357) 3003 124 (82–197) 0.14
Glycosuria (2 + or more) 108 140 (8–219) 3000 123 (82–197) 0.27
Hyperglycaemia during pregnancy 200 123 (78–217) 1786 123 (82–192) 0.94
Anaemia during pregnancy 214 123(91–202) 1772 123 (81–193) 0.35
Anaemia < 14 days postpartum 372 119 (82–190) 2734 124 (82–199) 0.27
Postpartum haemorrhage 274 116 (79–192) 1677 124 (82–195) 0.34
Preterm delivery 146 122 (82–197) 2976 124 (82–198) 0.92
Mode of delivery Caesarean section Vaginal delivery
330 125 (84–203) 1599 123(81–196) 0.53
Type of vaginal delivery Assisted/breech Spontaneous
393 122 (78–195) 1206 123 (82–196) 0.55
Customised birthweight 3
Small for gestational age Adequately grown for gestational age
203 125 (80–207) 1566 124 (82–198) 0.89
Large for gestational age Adequately grown for gestational age
185 115 (79–164) 1566 124 (82–198) 0.14
1 Values are median (25th, 75th percentile). 2 p value from Mann–Whitney U non-parametric tests. 3 Customized for
maternal BMI, parity, sex and gestational age [34].
4. Discussion
This is one of the first cohort studies in an overall mildly-to-moderately iodine-deficient pregnant
population to document that iodine insufficiency and more-than-adequate iodine status is not
associated with pregnancy or infant loss up to 1 year of age, or with other adverse obstetric outcomes.
It has been proposed that the potential adverse effects of severe iodine deficiency in pregnancy
are mediated through maternal thyroid dysfunction as iodine is an essential constituent of thyroid
hormones. Indeed, overt hypothyroidism during pregnancy, caused by conditions other than
iodine deficiency, has been associated with increased risk of pregnancy loss, preterm delivery,
pre-eclampsia, pregnancy-induced hypertension, low birthweight, caesarean delivery, antenatal
anaemia and post-partum haemorrhage [36,37]. At an individual level, thyroid function parameters
are, however, unreliable indicators of iodine status because of the homeostatic capacity to compensate
for mild-to-moderate iodine deficiency [38]; pregnant women can have normal thyroid function even
when mildly iodine deficient. The possibility of an alternative mechanism (other than through maternal
thyroid dysfunction) which could mediate the potential adverse effects of iodine deficiency upon
pregnancy has to be considered. The results of our study show that both mild iodine insufficiency
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and mild iodine excess are not associated with pregnancy and infant losses, and other obstetric
outcomes. This might suggest that maternal and fetal-placental tissues, other than the thyroid and
brain, are not particularly sensitive to minor perturbations in iodine availability and can continue to
function normally in pregnancy. However, given the low number of pregnancy and infant losses in our
study, it is also possible that our study was underpowered to detect the effects of iodine insufficiency.
Many of the previous studies evaluating iodine status in pregnant women living in mildly
iodine-deficient countries have reported obstetric outcomes independent of the effects of maternal
thyroid function. Consistent with our results on pregnancy/infant loss, a prospective study of
a mildly iodine-deficient pregnant population in Thailand using UIC measurements in a smaller
cohort [14] reported no association between pregnancy loss and iodine insufficiency, but the study
was underpowered to examine this. In our study, we found no significant difference in median
iodine-to-creatinine ratio between those with pregnancy/infant loss and those with babies alive at
1 year. Although the median UI/Creat was higher in those with pregnancy/infant loss (though not
significantly), this is most likely explained by fact that urine samples were collected significantly
later in pregnancy in those with a pregnancy/infant loss; in ALSPAC, as in other UK studies
iodine-to-creatinine increases across gestation [25].
We found no association with pregnancy outcomes, which is in contrast to the study in Thailand,
where an increase in preterm birth and low birthweight with iodine insufficiency was reported [14].
Birthweight has also been associated with maternal iodine status in a study of mildly deficient pregnant
women in Spain, where a lower likelihood of being small for gestational age was reported for women
with a UIC in the third trimester of between 100 µg/L and 149 µg/L compared with women with
a UIC below 50 µg/L [39]. This is in contrast to our study, where we found no association between
iodine status throughout pregnancy and likelihood of being small for gestational age.
The Generation R birth cohort in the Netherlands, which recruited from a pregnant population
with optimal iodine status, showed that the subset of women with urinary iodine below the 10th
percentile (equivalent to mild iodine insufficiency) were less likely to experience an operative delivery,
both instrumental and caesarean section [40]. This is in contrast to our results in the ALSPAC
cohort where the lowest assisted delivery rate was actually observed in the iodine-sufficient group
(150–249 µg/g), although the difference was not statistically significant. However, consistent with our
findings, the Generation R cohort [40] also did not detect any difference in gestational age at delivery
nor in birth weight, unlike the Thai cohort [14].
The reasons for these discrepancies are unclear. It may suggest that different confounding
factors associated with iodine insufficiency could be at play in influencing obstetric outcomes in
different settings. In the absence of good methods which can be used to assess individual iodine
status we are limited to assessing iodine status of whole populations, thus the challenge has always
been to determine the normal baseline rate of specific obstetric complications in an iodine-sufficient
population, and whether the observed complication rate in an iodine-insufficient population could
be improved with better iodine status. Even the recently reported clinical trial conducted in India
and Thailand, which showed no change in the rates of preterm birth or low birth-weight infants with
iodine supplementation in pregnancy, was confounded by the spontaneous improvement in urinary
iodine concentration in the placebo group as gestation progressed, such that controls were no longer
iodine insufficient by the end of pregnancy [15] and the fact that the women were not very iodine
deficient at baseline.
The strength of our study is the relatively large sample size of a pregnant population that is
not exposed to any universal iodination programme, and the prospective nature of the study where
iodine status was evaluated in a urine sample taken before the occurrence of the adverse events of
interest. Because of the sample size we were able to stratify pregnant women into four categories of
iodine status for comparison. A limitation of our study is the use of a single time-point spot urinary
iodine measure for categorisation of iodine status which may be a poor proxy of individual iodine
status [41], so misclassification is possible and could have masked any possible differences between
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groups. The causes of perinatal and child loss were diverse and the numbers were too small to evaluate
if specific causes were more likely to be associated with maternal iodine status. Also, the impact
of iodine status on early pregnancy miscarriages could not be studied because urine samples were
not collected from these women. Our study is underpowered to detect small differences in outcome
incidences and to assess rarer but significant obstetric complications, such as placental abruption.
It is also limited in exploring the effects of high iodine status (more-than-adequate or excessive) on
pregnancy outcomes as the population of women in ALSPAC were iodine deficient and most women
were in the iodine-deficient categories. The majority of participants in ALSPAC were White and had
indicators of higher socio-economic position [29] so our findings may not replicate in other ethnic and
socioeconomic groups.
5. Conclusions
In conclusion, our present study in a mildly-to-moderately iodine-deficient population without
an iodised salt programme did not find an association between iodine status and pregnancy outcomes
or child loss. Further research in this area is required, given the small number of studies that have
evaluated pregnancy outcomes and iodine status, and given the low numbers of women in our study
with pregnancy/infant loss.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/10/3/291/s1,
Table S1: Demographic characteristics according to grouped urinary iodine-to-creatinine ratio (UI/Creat) from the
first trimester only, Table S2: Likelihood of each adverse pregnancy outcome in urine-to-creatinine (UI/Creat)
group for first trimester samples only, Table S3: Comparison of urinary iodine-to-creatinine ratio (UI/Creat; µg/g)
in the first trimester only in those where pregnancy complications were either present or absent.
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